Official 2024 U.S. DOL Form 5500 summary for Alnylam Pharmaceuticals, INC. (Alnylam Pharmaceuticals, INC. Savings & Investment Plan · EIN 04-3696884 · PN 001): $344.00M net assets, 1,815 active participants, and $11.68 per $10,000 (11.68 bps).
| Plan Sponsor | Alnylam Pharmaceuticals, INC. |
|---|---|
| Filing Identifier | Alnylam Pharmaceuticals, INC. Savings & Investment Plan · EIN 04-3696884 · PN 001 |
| Plan Category & State | 401(k) Defined Contribution (MA) |
| Asset-Size Peer Cohort | $100M-$500M |
| Plan Net Assets (2024) | $344.00M |
| Active Participants | 1,815 |
| Direct Admin Fee Rate | $11.68 per $10,000 (11.68 bps) |
| Cohort Peer Median | $9.75 per $10,000 (9.75 bps) |
| Primary Recordkeeper / Provider | Fidelity Investments |
| Schedule H Line 4a Remittance | Timely Employer Remittance (0 reported on Line 4a) |
Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI
Verified federal filings reconciled for Alnylam Pharmaceuticals across sibling Meru AI platforms.